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Abstract
Background: Deep vein thrombosis (DVT) is a common complication of peripherally inserted central catheters
(PICCs). PICCs are increasingly utilised in the management of cancer patients, a group which carries both additional
risks for vascular thromboembolism as well as for complex morbidity. We analysed a cohort of cancer patients
subjected to PICC insertion in a single cancer centre for the incidence of all-type vascular thromboembolism
(VTE) and investigated relative risk factors.
Methods: In this clinical audit, the records of patients referred for PICC insertion in our centre in the period
between 1/1/2011 and 1/4/2014 were retrospectively reviewed. The primary outcomes investigated were a)
PICC-related deep vein thrombosis (PRDVT) and b) distant VTE (lower limb DVT and pulmonary embolism).
4Fr single lumen PICCs were placed in all patients. The Kaplan Meier method was used to study time from PICC
insertion to PRDVT/VTE. Survival curves were compared using the log rank method. Logistic and Cox regression
analyses were used to assess local, distant and combined endpoints.
Results: Four hundred ninety patients were included in the analysis of which 27 (5.5%) developed a PRDVT.
Statistically significant risk factors for developing PRDVT in multivariate analysis included more than one attempt
for insertion (OR 2.61, 95%CI: 1.12–6.05) and the use of fluoropyrimidine containing chemotherapy (OR 4.27, 95%CI
1.3–14.07). Twenty-six patients developed a distant VTE. Male gender was the only significant risk factor for distant
VTE. When all-type VTE were considered together fluoropyrimidine containing chemotherapy (OR 4.54, 95% CI
1.63–12.61), male gender (OR 2.03, 95% CI 1.04–3.93) and white cell count (OR 1.12, 95% CI 1.00–1.26) were
statistically significant as risk factors in this analysis.
Conclusions: This is a large study of VTE following PICC insertion in cancer patients which also looks at the rate of
distant VTE. The observed PRDVT incidence is comparable with available literature. Fluoropyrimidine containing
chemotherapy and more than one attempt for PICC insertion were independent predictors of PICC-associated VTE
whilst the former remained an independent predictor of all-type VTE. Anticoagulation did not prevent thrombotic
events in this cohort.
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Background
The use of peripherally inserted central catheters
(PICCs) is increasing, especially in the management of
cancer patients. [1, 2]. PICCs can be fitted at the bedside
by nurse-led teams, they are safer and more cost-
effective than other central venous catheters (CVCs) [3–
5]. Despite the benefits, PICC insertion has been shown
to increase the risk of venous thromboembolism (VTE)
particularly arm deep vein thrombosis (DVT) and pul-
monary embolism (PE) [4, 6–8]. These events have been
shown to occur commonly, to incur increased cost and
to be associated with increased morbidity [9]. In cancer
patients the risks may be higher [10]. A review address-
ing 16 studies, including 2169 cancer patients with
CVC, found symptomatic DVT in 262 (12%) of patients
[11]. This increased risk of VTE is important as these
patients have increased morbidity and mortality, require
prolonged antithrombotic treatment and may have med-
ical treatment e.g. chemotherapy interrupted [3]. Very
little work has been carried out looking at the incidence
and risk factors for VTE in cancer patients following the
insertion of PICCs. Published data has focused on all
CVCs of which just 15% were PICCs [12]. Two cohort
studies published in 2006 and 2012 found a PICC-
related DVT (PRDVT) rate of 4.3 and 5.6% respectively
with number of insertion attempts, ovarian cancer, pre-
vious CVC insertion, comorbidities and advanced dis-
ease being significant risk factors [1, 13].
In the present study we analyse our experience with
PICC insertion in cancer patients and investigate the in-
cidence of local and distant VTE and relative risk
factors.
Methods
This clinical audit consisted of a retrospective cohort
study of all patients who received a PICC line be-
tween 1st January 2011 and 1st May 2014 at the
Queens Centre for Oncology and Haematology, a
tertiary cancer unit of the Hull and East Yorkshire
NHS Hospitals Trust. All patients had active malig-
nancy and required a PICC for chemotherapy or
supportive treatment e.g. intravenous fluids or total
parenteral nutrition. PICCs were inserted by a team
of trained nurses under ultrasound guidance. The tip
position was confirmed with chest radiograph, with
the target site for the tip of the line being the cavo-
atrial junction or the distal third of the superior
vena cava.Lines were repositioned correspondingly.
The PICC inserted is the Groshong® single lumen
closed ended catheter under ultrasound guidance
using the SonoSite Nanomaxx® machine. There was
no routine use of thromboprophylaxis but if patients
were taking antithrombotic therapy for other reasons
this was recorded.
Patients developing PRDVT or distant VTE were all
treated with therapeutic doses of LMWH as per institu-
tional protocol. The agent used at our institute is Dalte-
parin and treatment was weight-adjusted, as per the
SmPC for this agent.
The primary outcome of the analysis was the PRDVT.
Data were collected for the secondary outcome of dis-
tant VTE (lower limb DVT and PE) at the same time.
PRDVT was defined as symptomatic DVT in the upper
limb vasculature ipsilateral to the PICC. Patient demo-
graphics, site and side of insertion, number of insertion
attempts, catheter repositioning, reason for insertion,
chemotherapy, cancer type, haemoglobin, white cell
count and platelet count were prospectively recorded in
a database for all patients undergoing a PICC insertion
attempt. Outcome data was collected retrospectively by
two of the authors (DJ, KW) who reviewed the elec-
tronic medical records of all patients including all radi-
ology reports. All VTE-positive radiology reports
documented the presence and site of thrombosis as per
institutional guidelines. PRDVT and distant limb DVT
was diagnosed with Doppler US in the presence of clin-
ical suspicion (symptoms). PEs reported include both
suspected (diagnosed with CTPA in the presence of
symptoms) as well as incidentally-identified PEs (diag-
nosed with standard, 1 mm slice, CT thorax with intra-
venous contrast performed for cancer staging).
Subsegmental PEs were included.
Time to PRDVT or distant VTE event was studied
with the Kaplan Meier method and was calculated from
the date of PICC insertion. Survival curves were com-
pared using the log rank method. Logistic regression and
Cox regression analyses were utilised to assess the effect
of different baseline factors for the local (PRDVT), dis-
tant (lower limb DVT and PE) and combined (all VTE)
endpoints. In all analyses a threshold of 5% was assumed
for statistical significance.
Results
During the study period 552 patients were referred for
PICC insertion. Of these patients, 54 (9.8%) were ex-
cluded from the present analysis as they did not have a
successful insertion. A further eight patients were ex-
cluded due to recording of incorrect patient ID num-
bers. This left 490 patients with complete data, eligible
for analysis. Median follow-up was 286 days. The me-
dian age of patients was 65 with a range of 24 to 89.
Two hundred seventeen patients were male. The most
common primary diagnosis was colorectal cancer
(n = 247, 50.4%), followed by breast cancer (n = 89,
18.2%) and pancreatic cancer (n = 39, 8%). PICC line
was successfully inserted on the first attempt in 364
(74.3%) of patients. 42 (8.6%) patients were on anti-
thrombotic therapy prior to PICC insertion [atrial
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fibrillation n = 6 (14%), previous VTE n = 32 (76%),
thrombophilia n = 1, primary prophylaxis n = 1], the
majority (n = 28, 67%) on LMWH (at therapeutic doses
except one case on enoxaparin 40 mg o.d.). The most
common reason for anticoagulation was a previous VTE
(n = 26, 62%). Baseline groups and PRDVT/distant VTE
incidence are shown in Table 1.
PRDVT developed in 27 (5.5%) of the 490 patients
in the cohort. Distant VTE developed in 26 patients
(5.3%). All-type VTE (i.e. PRDVT or distant VTE)
was identified in 52 (10.6%) patients with one patient
having a PICC related DVT followed by a PE. Median
time until the development of PICC-related DVT,
other VTE and all type VTE was 21 days 95% Confi-
dence Interval [CI] (14, 28), 55 days 95% CI (29, 81)
and 43 days 95% (CI – 23, 63) respectively. The inci-
dence of PE was 4% (n = 21) corresponding to 40%
of all-type VTE events. The majority (n = 17, 81%) of
PE events were incidental findings in staging CT
thorax. One (5%) patient with PE had a concomitant
subclavian and axillary vein PRDVT. Median time to
PE was 55 days 96% CI (19, 91) amongst the patients
who developed PRDVT the most proximal vein af-
fected was the jugular in 4 (14.8%) patients, the sub-
clavian in 14 (51.8%), the axillary in 4 (14.8%) and
the brachial in 5 (18.5%).
Amongst the 42 patients on anticoagulation at the
time of PICC insertion, 4 all-type VTE events were ob-
served (9.5%) including 3 PICC-related DVT’s and one
distant VTE at a median of 54 days 95% CI (0, 115).
Exploratory survival analyses indicated eight factors
with potential predictive value. These factors were in-
cluded in a logistic regression model (Table 2).
Logistic regression (Table 2) indicated that requiring
more than one attempt at insertion of PICC line more
than doubled the risk of PICC related DVT (Odds Ratio
[OR] 2.61, 95% Confidence Interval [CI] 1.12,6.05). The
use of Fluoropyrimidine chemotherapy increased the risk
by four-fold (OR 4.27, 95% CI 1.30, 14.07). No other fac-
tor was a significant predictor of PRDVT. When consid-
ering distant VTE events, male gender was a significant
risk factor (OR 3.82 95% CI 1.34, 10.87) and when all
VTEs were considered together, fluoropyrimidine con-
taining chemotherapy (OR 4.54 95% CI 1.63, 12.61), be-
ing male (OR 2.03 95% CI 1.04, 3.93) and white cell
count (OR 1.12 95% CI 1.00, 1.26) were significant.
Discussion
PRDVT is a common problem for cancer patients, which
could interrupt potential cancer treatment and cause sig-
nificant morbidity. This study found a PICC related
DVT rate of 5.5% which is in keeping with the rate
Table 1 Tabulation of patient demographics, baseline characteristics, PICC-related and distant DVT/VTE incidences
Characteristic All patients
(n = 490)
PICC-related DVT
(n = 27)
Distant VTE
(n = 26)
Age (Mean) 62.4 63.0 67.9
Gender
Male 217 (44.3%) 13 (5.9%) 21 (9.7%)
Female 273 (55.7%) 14 (5.1%) 5 (1.8%)
Primary cancer
Colorectal 247 (50.4%) 19 (7.6%) 22 (8.9%)
Breast 89 (18.2%) 6 (6.7%) 1 (1.1%)
Pancreas 39 (8%) 2 (5.1%) 1 (2.6%)
Other 115 (23.4%) 0 2 (1.7%)
Treatment intention
Adjuvant 194 (39.6%) 16 (8.2%) 15 (7.7%)
Palliative 258 (52.7%) 11 (4.2%) 10 (3.9%)
Neo Adjuvant /Radicala 28 (5.5%) 0 0
Supportiveb 10 (2.2%) 0 1 (10%)
Catheter insertion
More than one insertion attempt 126 (25.7%) 11 (8.7%) 4 (3.1%)
Catheter repositioning 241 (49.2%) 15 (6.2%) 13 (5.4%)
Current anticoagulation 42 (8.6%) 3 (7.1%) 1 (2.4%)
DVT deep vein thrombosis, PICC peripherally inserted central catheter, VTE vascular thromboembolism
One patient had both PICC related DVT and distant VTE (PE)
aNeo adjuvant/Radical – Treatment with curative intent
bSupportive – intravenous fluids or total parenteral nutrition
Jones et al. Thrombosis Journal  (2017) 15:25 Page 3 of 6
found in the two other studies on PICC related DVT in
cancer patients [1, 13].
A recent study which looked at PICC related throm-
bosis in all hospital patients found a slightly lower PICC
related DVT rate of 3% in a population almost devoid of
cancer patients [7]. The same study found a number of
significant risk factors for developing a PICC related
DVT which included previous DVT, PICC size, and sur-
gery lasting >1 h [7]. Grove et al. [14] reported an overall
venous thrombosis rate of 3.9%. This rate was different
when the lines were inserted by nurses (4.5%) compared
with radiologists (3.7%). They also identified that DVT
risk correlated to catheter diameter, with DVT rates of
0, 1, 6.6 and 9.8% for catheters sized <3-F, 4-F, 5-F and
6-F respectively, comparable (albeit slightly higher) to
the relative numbers reported by Evans et al. The im-
portance of lumen size was further highlighted in a
follow-on study by Evans et al. [15]. Cotogni and Pittir-
uti identified inappropriate choice of central venous ac-
cess device and insertion technique as important risk
factors for post-procedure complications, particularly in
critically ill patients [16]. In our study the catheter used
was uniform and all PICC insertions were conducted by
nurses under ultrasound guidance.
In the study by Aw et al. on PICC line insertion in
cancer patients, none of the above mentioned variables
were predictive of PRDVT. However, the study reported
that co-morbidities such as diabetes, COPD and ad-
vanced cancer did predict DVT [1]. Lee et al. identified
previous catheterisation, more than one insertion at-
tempt and ovarian cancer as being associated with an in-
creased incidence of DVT [13].
This is the only study to date to specifically consider
the rate of distant VTEs following PICC insertion in
cancer patients. We found distant VTEs in 26 patients
of which 20 had PEs and six had leg DVTs. One patient
had a PICC related DVT and went on to develop a PE.
Male gender was found to be a predictive factor. Whilst
it is recognised that cancer itself is a significant risk
factor for VTE, the published rate of VTE in cancer pa-
tients was 2% in a large study of 40 million cancer pa-
tients [17]. The rate of distant VTE is our study was
5.3% which suggests that PICC insertion might be con-
sidered as a possible risk factor for distant VTE as well.
Whilst LMWH is recommended as the current treat-
ment for oncology patients who have suffered a VTE
[18], anticoagulation did not exhibit a statistical effect
on the development of local or distant VTE in our co-
hort. Current evidence suggests that thromboprophy-
laxis to prevent these events has not been shown to be
effective, despite a number of randomised controlled tri-
als (RCTs). For example, the two larger prospective stud-
ies, one of LMWH [19] and one of warfarin (low fixed
and International Normalised Ratio [INR]-adjusted dos-
ing) [20] did not achieve their primary endpoints. More-
over a recent Cochrane Database meta-analysis of 12
RCTs enrolling a total of 3611 patients assessing either
primary prophylaxis dose heparins or low dose vitamin
K antagonists in cancer patients with CVCs failed to
demonstrate any benefit on the major endpoints studied
[21]. Therefore, current guidance does not recommend
thromboprophylaxis in the setting of a long-term CVC
in cancer patients.
The finding of the present study that the number of
insertion attempts is a risk factor for PRDVT points to
the role of disrupted endothelium during the process of
difficult cannulation [22]. This finding is supported by
Lee et al. [13] who found more than two attempts at in-
sertion was a significant predictor of PRDVT. Of interest
is the correlation with white blood cell count of all VTE
(one of the factors noted by Khorana et al.) which could
reflect tumour burden-related effects. Leukocytosis was
an independent predictor of VTE in an analysis of pa-
tients taking part in the REAL-2 study two arms of
which were treated with infusional chemotherapy requir-
ing central venous access devices [23]. ‘Inflammation’
has been well correlated with VTE in the literature but
the particular role of the raised neutrophil numbers also
Table 2 Logistic regression model of factors with potential predictive value indicated by exploratory survival analyses
Variable PICC related DVT Distant VTE All VTE
Odds Ratio (95%CI) p Odds Ratio (95%CI) p Odds Ratio (95%CI) p
Male 0.97 (0.41,2.28) 0.94 3.82 (1.34,10.87) 0.01* 2.03 (1.04,3.93) 0.04*
Age (cont.) 1.01 (0.98,1.05) 0.54 0.97 (0.93,1.01) 0.24 0.99 (0.96,1.02) 0.53
More than one insertion attempt 2.61 (1.12,6.05) 0.03* 0.69 (0.22,2.16) 0.53 1.53 (0.76,3.06) 0.22
Catheter repositioning 1.29 (0.57,2.96) 0.54 1.44 (0.61,3.41) 0.41 1.25 (0.86,2.35) 0.47
Current anticoagulation 1.16 (0.31,4.39) 0.82 0.22 (0.02,1.74) 0.21 0.54 (0.17,1.68) 0.15
White Cell Count 1.10 (0.95,1.28) 0.19 1.14 (0.96,1.34) 0.13 1.12 (1.00,1.26) 0.04*
Fluropyrimidine containing chemotherapy 4.27 (1.30,14.07) 0.02* 7.77 (0.95,63.3) 0.06 4.54 (1.63,12.61) 0.01*
Bevacizumab containing chemotherapy Not applicable Not applicable 0.57 (0.12,2.65) 0.48 0.25 (0.06,1.08) 0.06
DVT deep vein thrombosis, PICC peripherally inserted central catheter, VTE vascular thromboembolism, CI confidence interval
* = P <0.05 statistically significant
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suggest that this could be a clinical parameter that re-
flects the increasingly recognised role of neutrophil
extracellular traps in the initiation of VTE [24].
Through this study, we are able to report an influence
of the type of chemotherapy on the rate of PRDVT.
Chemotherapy has been shown to increase the risk for
VTE in general by more than two-fold [25]. In our study
in which the majority of our patients were receiving sys-
temic antineoplastic treatment, 5-fluorouracil specifically
was associated with an increased risk of PICC-associated
thrombosis and all type VTE whilst a trend for an in-
creased risk for distant VTE was also observed. This ef-
fect could be explained by the well-known pro-
thrombotic and endothelial effects of 5-fluorouracil [26].
We also observed a trend for increased distant VTE with
bevacizumab. It should be noted that our study did not
capture arterial events which may be more relevant for
this agent.
This study was subject to some limitations. It did not
include thrombotic events associated with long-term
skin tunnelled catheters, cited as having a lower inci-
dence compared to PICC-related VTE [27]. We were
not able to report on the effect of the catheter to vein
diameter ratio on the incidence of thrombotic events
since it is not part of the standard insertion protocol in
our centre and therefore was not recorded. Preclinical
evidence suggests that increasing catheter to vein diam-
eter ratio may dramatically restrict blood flow through
the veins [28, 29] whilst clinical data suggest that a cath-
eter to vein diameter ratio of >45% may increase the
likelihood of VTE 13-fold [30, 31]. As a retrospective co-
hort study, we were unable to obtain data on certain pa-
tient demographics such as body mass index, smoking
status, comorbidities and patient mediations. This meant
that we could not test the risk factors found by Aw et
al., [1]. It is possible that the confounding variables we
have been unable to record may have had an impact on
PICC related DVT rates in this study. Selection bias was
minimised by including all patients who had a successful
PICC insertion in the study period. This study addressed
suspected PRDVT events only and therefore did not
capture subclinical thrombotic events that may have
been identified with planned investigations. Conversely,
this rendered the study within pragmatic confines, docu-
menting clinically significant events.
Finally, it is of note that our institutional guide-
lines are compatible with the recent Michigan Ap-
propriateness Guide for Intravenous Catheters
(MAGIC) comprehensive recommendations, which
aim to minimise PICC-related complications [29, 32];
however, the present study was conducted prior to
the relevant publication and therefore did not inves-
tigate all corresponding care and maintenance end-
points in individual patients.
Conclusion
This is a large study looking at PRDVT, solely in cancer
patients and confirms the incidence of PRDVT as docu-
mented in the literature. It also suggests that PICC in-
sertion increases the risk of ‘distant VTE’ (PEs and
lower limb DVTs) in these patients. This correlates with
the findings of other studies of VTE’s associated with
peripherally inserted central catheters in patients with,
or without cancer [31, 32]. This study did not find any
strong predictors of PICC-related DVT. To improve our
understanding of DVT development associated with
PICC insertion and the predicted risk factors, further
large, prospective studies with carefully pre-planned data
capture would be required.
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